System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish 15 citations

PubMed: 37979154 DOI: 10.1080/19490976.2023.2274126

Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis.

Gut Microbes 15(2):2274126

Authors: Dorota Kujawa, Lukasz Laczmanski, Slawomir Budrewicz, Anna Pokryszko-Dragan, Maria Podbielska

Affiliations

  • Laboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
  • Laboratory of Microbiome Immunobiology, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.

Abstract

Multiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function of the gut microbiota. In this review, current experimental and clinical evidence is presented for the characteristics of gut dysbiosis found in MS, as well as for its relevant links with the course of the disease and the dysregulated immune response and metabolic pathways involved in MS pathology. Furthermore, therapeutic implications of these investigations are discussed, with a range of pharmacological, dietary and other interventions targeted at the gut microbiome and thus intended to have beneficial effects on the course of MS.

MeSH

Multiple Sclerosis, Microbiota, Therapeutics, Prebiotics, Probiotics, Diet, Gastrointestinal Microbiome

Cited by